Gastrointestinal Stromal Tumor (GIST) News and Research

RSS
Gastrointestinal Stromal Tumor (GIST) is a type of tumor that usually begins in cells in the wall of the gastrointestinal tract. It can be benign or malignant.
OHSU Knight Cancer Institute Director wins 2018 Tang Prize in Biopharmaceutical Science

OHSU Knight Cancer Institute Director wins 2018 Tang Prize in Biopharmaceutical Science

Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

AACR rapid and dramatic responses in TRK fusion patients

AACR rapid and dramatic responses in TRK fusion patients

FDA accepts Blueprint Medicines' IND applications to start Phase 1 clinical trials for two drug candidates

FDA accepts Blueprint Medicines' IND applications to start Phase 1 clinical trials for two drug candidates

Bayer enrolls patients for Phase III trial of Stivarga (regorafenib) tablets in colorectal cancer

Bayer enrolls patients for Phase III trial of Stivarga (regorafenib) tablets in colorectal cancer

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Blood test reveals more gene mutations in cancer than traditional tumor biopsy

Blood test reveals more gene mutations in cancer than traditional tumor biopsy

Glimmer of hope for imatinib-resistant GIST

Glimmer of hope for imatinib-resistant GIST

Bowel cancer and GIST patients could benefit from novel oral drug

Bowel cancer and GIST patients could benefit from novel oral drug

AB Science announces data from development program of masitinib in GIST

AB Science announces data from development program of masitinib in GIST

New preclinical data on ARIAD's ponatinib and AP26113 study presented at AACR meeting

New preclinical data on ARIAD's ponatinib and AP26113 study presented at AACR meeting

Three new targeted drugs can lead to fatal cancer complications

Three new targeted drugs can lead to fatal cancer complications

Threshold commences combination Phase 1/2 trial of TH-302 and sunitinib for RCC, GIST and PNET

Threshold commences combination Phase 1/2 trial of TH-302 and sunitinib for RCC, GIST and PNET

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

FDA approves SUTENT for treatment of pancreatic NET

FDA approves SUTENT for treatment of pancreatic NET

Research on rare cancers

Research on rare cancers

European Commission approves Pfizer's SUTENT for pancreatic neuroendocrine tumors

European Commission approves Pfizer's SUTENT for pancreatic neuroendocrine tumors

Pfizer ceases SUN 1120 Phase 3 trial of SUTENT in men with CRPC

Pfizer ceases SUN 1120 Phase 3 trial of SUTENT in men with CRPC

Pfizer reports Progression-Free survival in SUN 1087 combination trial of sunitinib with erlotinib for NSCLC

Pfizer reports Progression-Free survival in SUN 1087 combination trial of sunitinib with erlotinib for NSCLC

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010